This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Cerner's (CERN) Acquisition by Oracle to Boost Patient Outcome
by Zacks Equity Research
Cerner's (CERN) buyout is likely to aid in growing its community presence as well as improve patient outcomes.
STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment
by Zacks Equity Research
The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.
3 Promising Gene Sequencing Stocks to Watch Out For in 2022
by Trina Mukherjee
Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.
Integra (IART) Businesses Rebound Despite Supply Issues
by Zacks Equity Research
Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.
Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M
by Zacks Equity Research
Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.
Medtronic (MDT) Businesses Rebound Amid Raging Pandemic
by Zacks Equity Research
Medtronic (MDT) is registering strong organic growth in the Cardiovascular, Neuroscience and Diabetes segments on product launches.
Bruker (BRKR) Introduces JPK NanoWizard V for AFM Research
by Zacks Equity Research
Bruker's (BRKR) newly-introduced JPK NanoWizard V is expected to significantly contribute to life science atomic force microscopy investigations.
Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.
Here's Why You Should Retain DexCom (DXCM) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Accuray's (ARAY) CyberKnife System Gets Shonin Approval
by Zacks Equity Research
Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Thermo Fisher Scientific (TMO) and West Pharmaceutical Services (WST) have performed compared to their sector so far this year.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.
Here's Why You Should Retain Haemonetics (HAE) Stocks for Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.
Medtronic's (MDT) INVOS System Gets FDA 510 (k) Clearance
by Zacks Equity Research
Medtronic's (MDT) INVOS 7100 system can deliver key signals to pediatric clinicians for making time-sensitive decisions
Avantor (AVTR) to Improve Biopharma Supply Chain With New Site
by Zacks Equity Research
Avantor's (AVTR) new logistics hub in Westminster is intended to support growth of single-use businesses.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher Scientific, Salesforce, Nike and Texas Instruments
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Thermo Fisher Scientific, Salesforce, Nike and Texas Instruments
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its robust facility expansion activities and a slew of strategic deals.
Top Research Reports for Berkshire Hathaway, Thermo Fisher & salesforce
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Thermo Fisher Scientific Inc. (TMO), and salesforce.com, inc. (CRM).
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about NEOGEN (NEOG) given robust sales growth in the Food Safety business and impressive international performance.
Here's Why You Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental growth and bullish 2022 outlook.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $661.25, marking a +0.84% move from the previous day.